AUROPHARMA - Technical Analysis with Chart Patterns & Indicators

Last Updated Time : 20 Dec 25, 03:54 pm

Technical Rating: 4.2

📊 Chart Patterns & Trend: AUROPHARMA is in an uptrend, trading above both 50 DMA (1,171 ₹) and 200 DMA (1,155 ₹). The stock has recently tested resistance near 1,365 ₹ and is consolidating just below this level.

📈 Moving Averages:

- Current price (1,225 ₹) is above both 50 DMA and 200 DMA, confirming bullish momentum.

- Golden cross setup (price above both averages) supports continuation of trend.

📉 RSI: At 56.3, RSI is moderately bullish, indicating room for further upside before overbought territory.

📈 MACD: Positive (4.24), showing bullish crossover and strengthening momentum.

📊 Bollinger Bands: Price is near the upper band, suggesting strong buying interest but also potential short-term resistance.

📊 Volume Trends: Current volume (11,90,235) is significantly higher than 1-week average (6,67,656), indicating strong participation and accumulation.

🎯 Entry Zone: 1,200–1,215 ₹ (near support at 50 DMA).

🎯 Exit Zone: 1,350–1,365 ₹ (near recent high resistance).

⚡ Support Levels: 1,170 ₹ and 994 ₹ (major support).

⚡ Resistance Levels: 1,365 ₹ and 1,400 ₹.

Positive

• Strong uptrend with price above both 50 DMA and 200 DMA.
• High trading volume indicates strong investor interest.
• Quarterly PAT growth (581 Cr. vs 559 Cr.) shows consistent performance.
• DII holdings increased (+0.67%), reflecting domestic institutional confidence.

Limitation

• High P/E (35.2) compared to industry average (30.6).
• ROE (8.65%) and ROCE (10.8%) remain modest.
• PEG ratio (8.25) suggests expensive valuation relative to growth.
• FII holdings declined (-0.17%), showing reduced foreign investor interest.

Company Negative News

• Valuation concerns with high P/E and PEG ratio.
• Profit growth is moderate (8.16% QoQ), not aggressive.

Company Positive News

• Consistent quarterly profit growth with PAT at 581 Cr.
• EPS of 34.8 ₹ supports long-term earnings visibility.
• Strong volume surge indicates accumulation phase.

Industry

• Industry P/E at 30.6, slightly lower than AUROPHARMA, suggesting premium valuation.
• Pharma sector remains defensive with steady demand outlook.

Conclusion

⚖️ AUROPHARMA is trending upward with bullish signals from MACD, RSI, and moving averages. Strong volume confirms momentum, but valuations remain stretched. Short-term traders can enter near 1,200–1,215 ₹ with exits around 1,350–1,365 ₹. The stock is currently trending with consolidation near resistance, awaiting breakout above 1,365 ₹ for further upside.